Involvement of the Genetic Diversity of HIV-1 in the Virological Treatment Failure of First Line Antiretroviral in Kinshasa

Kamangu, Erick Ntambwe; Kalala, Richard Lunganza; Mvumbi, Georges Lelo; Vaira, Dolorès; Hayette, Marie‐Pierre

doi:10.4236/wja.2017.71003

Cited by 3 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This EWI was respected at 58% of all ATCs thus giving a rate of 42% of patients lost sight in the first year while the targeted objective is less than 20% of patients lost of sight. This high rate of patients lost of sight had also been presented in previous studies in Kinshasa [9] [10]. This high rate of patients lost of sight was most likely due to the fact that most patients are not well aware of the fact that ART is a treatment for life once it is started; regardless of the improvement in the state of health.…”

Section: Discussionsupporting

confidence: 73%

Evaluation of Early Warning Indicators (EWI) of HIV Drug Resistance According to the World Health Organization (WHO) in Some Treatment Centers in Kinshasa

Okonda¹,

Bulanda²,

Kabasele³

et al. 2019

OALib

Self Cite

View full text Add to dashboard Cite

Background: The Early Warning Indicators (EWI) of Human Immunodeficiency Virus (HIV) Drug Resistance measure factors found at the site level and known to be associated with the proper functioning of the program and the prevention of the emergence of R-ARV. The fact strengthening certain aspects of implementation of the program at the sites can help minimize the occurring of HIV Drug Resistance that can be prevented to improve the long-term effectiveness and sustainability of the treatment. Objective: The objective of this study was to assess the quality of the prevention of resistance of HIV Drug compared to EWI set by the World Health Organization (WHO) in the different Ambulatory Treatment Centers (ACT) in the city of Kinshasa. Methods: The present work was a retrospective survey conducted in 2015 in 7 ACTs in the 4 districts of Kinshasa in order to evaluate the EWI. Results: Seven (7) ATCs and 157 patient records were selected based on different inclusion criteria. The maintenance of first-line Antiretroviral Treatment (ART) at 12 months and the consistent delivery of ARVs were the two EWI that were respected, evaluation at 100%, for 6 ACTs. Conclusion: The caregivers and HIV-infected patients should be trained on the EWI and their monitoring to prevent the occurrence of treatment failures and that of HIV drug resistance in Kinshasa.

show abstract

Section: Discussionsupporting

confidence: 73%

Evaluation of Early Warning Indicators (EWI) of HIV Drug Resistance According to the World Health Organization (WHO) in Some Treatment Centers in Kinshasa

Okonda¹,

Bulanda²,

Kabasele³

et al. 2019

OALib

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, the mutations K65R (2 cases), T69P/N (3 cases), K70R (5 cases) and M184V (5 cases) were listed as existing mutations for Nucleotide Reverse Transcriptase Inhibitors. This confirms the strong genetic barrier attributed to DTG in the different literature in the field [17]. However, the mutations found are generally associated with resistance to Lamivudine-3TC (K65, T69, M184) and Tenofovir-TDF (K70) [17].…”

Section: Discussionsupporting

confidence: 72%

“…This confirms the strong genetic barrier attributed to DTG in the different literature in the field [17]. However, the mutations found are generally associated with resistance to Lamivudine-3TC (K65, T69, M184) and Tenofovir-TDF (K70) [17]. As a result, more than 14.52% of patients on ART, or 36% of patients with virological failure, are in a situation of failure because of the mutation which confers resistance to TDF.…”

Section: Discussionsupporting

confidence: 60%

Virological Profile of People Living with HIV after 12 Months of Treatment with Dolutegravir in Kinshasa

Bongenya,

Sombo,

Bumoko

et al. 2023

WJA

View full text Add to dashboard Cite

Context: The evaluation of plasma Viral Load constitutes an indicator of the progression of the infection, the effectiveness and the tolerance of the treatment. Objective: The objective of this study is to present the virological profile of Patients Living with HIV (PLHIV) after 12 months of AntiRetro Viral Treatment (ART) based on Dolutegravir (DTG) in Kinshasa. Method: The present study is a cross-sectional view of the virological profile of the twelfth month of a prospective cohort of PLHIV at M12 of DTG-based ART in Kinshasa. During the M12 appointment, a blood sample was taken for Molecular Biology analyses from all PLHIV included. Result: During the M12 appointment, 28 patients were registered, including 16 (57.1%) women. Nine (9) patients (45.0%) had an undetectable Viral Load (VL). The median VL value was 3.18 log 10 RNA copies/mL (1530 RNA copies/mL). The mutations K65R, T69P/N, K70R and M184V have been listed as mutations conferring resistance to Nucleotide Reverse Transcriptase Inhibitors. No mutations associated with Dolutegravir were observed at M12. Conclusion: After 12 months of AntiRetroViral Treatment based on Dolutegravir, half of the Patients on first-line ART are in a state of virological failure.

show abstract

“…However, the mutations K65R (3 cases), T69P/N (6 cases), K70R (9 cases) and M184V (8 cases) were listed as existing mutations for Nucleotide Reverse Transcriptase Inhibitors. Even after the loss of patients, subtype A still remains dominant in the cohort of PLHIV on ART in Kinshasa, followed by CRF02 and subtype C. This is the profile presented for Kinshasa through the various available literatures [12] [13] [18]. After 6 months of ART, no mutation was found to induce resistance to DTG.…”

Section: Discussionmentioning

confidence: 90%

“…Reverse Transcription PCR (RT-PCR) and Nested PCR were performed on the extracted RNA to amplify regions of interest for Protease and Reverse Transcriptase (TR) for sequencing. The PCRs for sequencing were carried out under the conditions previously described in the literature [12] [13].…”

Section: Sequencing and Molecular Identificationmentioning

confidence: 99%

Virological and Molecular Profile of People Living with HIV after 24 Weeks of Treatment with Dolutegravir in Kinshasa

Bongenya,

Tshinguta,

Kabengele

et al. 2023

WJA

View full text Add to dashboard Cite

Context: The appointment of the M6 is crucial because it is an indicator of the prognosis of the evolution of the care and the decision-making on the continuation of the AntiRetroViral Treatment. Objective: The objective of this study is therefore to present the virological and molecular profile of People Living with HIV under treatment with Dolutegravir 6 months after being put on ART in Kinshasa. Methods: The present study is a cross-sectional view at the sixth month of a prospective cohort to determine the virological and molecular profile of People Living with HIV (PLHIV) after 6 months of ART based on Dolutegravir (DTG) in Kinshasa. A sample of 5 mL of blood was taken from all HIV patients included. The collection of biological data was carried out under the same conditions as at inclusion. After extraction, Quantitative Real-Time PCR was carried out to determine the quantity of HIV RNA in the samples according to the protocols previously described. Reverse Transcription PCR (RT-PCR) and Nested PCR were carried out to amplify the regions of interest for Protease and Reverse Transcriptase for sequencing. Results: The median VL value was 2.92 log 10 RNA copies/mL. With 17.75% of patients experiencing major failure of first-line treatment. Subtype A is dominant with 13 cases (20.98%); followed by CRF_02AG (16.13%), subtypes C (14.52%), D (9.68%) and K (6.45%). The K65R (3 cases), T69P/N (6 cases), K70R (9 cases) and M184V (8 cases) mutations were listed as existing muta-

show abstract

Involvement of the Genetic Diversity of HIV-1 in the Virological Treatment Failure of First Line Antiretroviral in Kinshasa

Cited by 3 publications

References 19 publications

Evaluation of Early Warning Indicators (EWI) of HIV Drug Resistance According to the World Health Organization (WHO) in Some Treatment Centers in Kinshasa

Evaluation of Early Warning Indicators (EWI) of HIV Drug Resistance According to the World Health Organization (WHO) in Some Treatment Centers in Kinshasa

Virological Profile of People Living with HIV after 12 Months of Treatment with Dolutegravir in Kinshasa

Virological and Molecular Profile of People Living with HIV after 24 Weeks of Treatment with Dolutegravir in Kinshasa

Contact Info

Product

Resources

About